Last reviewed · How we verify

NCT07297719

Evaluation of Glistening, Visual Outcomes and General Safety 24 Months Post-IOL Implantation

Completed Last updated 16 January 2026
What this trial tests

trial in Cataract Senile in 33 participants. Completed in 31 December 2025.

Timeline
25 December 2025
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorCarl Zeiss Meditec AG
StatusCompleted
Study typeOBSERVATIONAL
Enrollment33
Start date25 December 2025
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across China

Conditions studied

Sponsor

Carl Zeiss Meditec AG — full company profile →

Who can join

18 and older, any sex, with Cataract Senile. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Main evaluation of glistening at least 24 Months post-IOL implantation

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cataract Senile

Currently open trials in the same condition.

Other Carl Zeiss Meditec AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07297719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing